SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -92.42% | -95.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -92.42% | -95.87% |
| Cost of Revenue | 63.97% | 33.60% | 12.11% | 12.84% | 26.42% |
| Gross Profit | -64.61% | -35.35% | -17.32% | -19.07% | -43.00% |
| SG&A Expenses | 88.44% | 42.35% | 7.72% | -51.39% | -50.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.27% | 36.35% | 10.67% | -18.73% | -13.65% |
| Operating Income | -71.74% | -37.56% | -14.08% | 16.58% | 8.66% |
| Income Before Tax | 65.52% | 98.84% | 138.92% | 141.13% | 8.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.52% | 98.84% | 138.92% | 141.13% | 8.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.52% | 98.84% | 138.92% | 141.13% | 8.10% |
| EBIT | -71.74% | -37.56% | -14.08% | 16.58% | 8.66% |
| EBITDA | -78.38% | -42.42% | -20.34% | 14.38% | 5.64% |
| EPS Basic | 95.17% | 72.97% | 67.23% | 59.33% | 29.86% |
| Normalized Basic EPS | 182.10% | 166.86% | 161.52% | 123.81% | 29.86% |
| EPS Diluted | 72.53% | 48.55% | 42.72% | 47.09% | 29.78% |
| Normalized Diluted EPS | 89.93% | 67.31% | 61.55% | 60.75% | 29.86% |
| Average Basic Shares Outstanding | 416.92% | 227.54% | 108.50% | 11.65% | 21.77% |
| Average Diluted Shares Outstanding | 597.88% | 408.70% | 289.89% | 206.35% | 21.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |